Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (not Vivani Medical, Inc.) on August 30, 2017, reporting events occurring on August 28, 2017. The Company is a California-based medical device developer focused on the Orion Cortical Visual Prosthesis System, designed to restore vision to patients blinded by conditions such as glaucoma and diabetic retinopathy by directly stimulating the visual cortex.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes
The primary material event is the receipt of conditional approval from the U.S. Food and Drug Administration (FDA) to commence the Orion feasibility clinical study. This approval permits enrollment of up to five patients across two designated U.S. sites: the University of California at Los Angeles (UCLA) and Baylor College of Medicine in Houston.
Guidance, Outlook, and Risks
- Regulatory Conditions: The FDA approval is conditional. The agency has requested additional device testing and responses to outstanding questions.
- Timeline: The Company has 45 days from the approval date to respond to the FDA's requests.
- Technology: The Orion system bypasses the retina and optic nerve, using a miniature camera and wireless transmission to stimulate the visual cortex.
- Prior History: This follows a proof-of-concept trial announced in Q4 2016 using a commercially available device from a different manufacturer.
Investor Verification Checklist
- Verify the specific nature of the FDA's "outstanding questions" and the scope of additional device testing required.
- Confirm the Company's ability to meet the 45-day deadline for responding to the FDA.
- Monitor patient enrollment progress at the UCLA and Baylor College of Medicine sites.
- Review the attached press release (Exhibit 99.1) for detailed technical specifications of the conditional approval.